DeCure for Hematopoietic and lymphoid system neoplasm
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for hematopoietic and lymphoid system neoplasm — screening already-approved drugs against its 11-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHematopoietic and lymphoid system neoplasm maps to a 11-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hematopoietic and lymphoid system neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
splicing factor 3b subunit 1 (SF3B1) — SF3B1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2~{s},3~{s},4~{e},6~{s},7~{r},10~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7EVO · 2.5 Å · ligand [(2~{S},3~{S},4~{E},6~{S},7~{R},10~{R})-3,7-dimethyl-2-[(2~{E},4~{E},6~{R})-6-methyl-6-oxidanyl-7-[(2~{R},3~{R})-3-[(2~{R},3~{S})-3-oxidanylpentan-2-yl]oxiran-2-yl]hepta-2,4-dien-2-yl]-7,10-bis(oxidanyl)-12-oxidanylidene-1-oxacyclododec-4-en-6-yl] 4-cycloheptylpiperazine-1-carboxylate (9B0). Experimental structure, not a prediction.
What the evidence adds up to
The 2016 revision of the World Health Organization classification of lymphoid neoplasms reflects a consensus among hematopathologists, geneticists, and clinicians. It updates current entities, adds a limited number of new provisional entities, clarifies diagnosis and management of very early lymphomagenesis, refines diagnostic criteria, and details the expanding genetic and molecular landscape of lymphoid neoplasms and their clinical correlates. The revision refers to investigations leading to more targeted therapeutic strategies, with an emphasis on advances that impact diagnostic approach, clinical expectations, and treatment.
The International Consensus Classification of Mature Lymphoid Neoplasms, reported in 2022, followed the same process used for the third and fourth editions of the WHO classification. Definition, recommended studies, and diagnostic criteria for many entities have been extensively refined. Some provisional categories have been upgraded to definite entities, and terminology for some diseases has been revised where well-justified. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria, and these changes will have an impact on optimal clinical management. The classification covers mature lymphoid, histiocytic, and dendritic cell tumors.
For myelodysplastic and myeloproliferative neoplasms, the WHO classification includes chronic myelomonocytic leukaemia, atypical chronic myeloid leukaemia (BCR-ABL1 negative), juvenile myelomonocytic leukaemia, and unclassifiable cases. The best characterised unclassifiable condition is the provisional entity refractory anaemia with ringed sideroblasts associated with marked thrombocytosis.
No drug, no treatment, no survival or response data are reported in any of these abstracts. The abstracts describe classification frameworks, not clinical trials. What is still missing is any evidence that these refined diagnostic categories or genomic insights have been tested in prospective trials that link specific molecular subtypes to effective treatments. The field lacks randomised studies that stratify patients according to the new consensus definitions and measure outcomes such as survival or response. Funding for such trials, rather than further classification work, remains the gap.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Blood · 2016 · 7853 citations · open access
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
AbstractA revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations, and therapeutic strategies for the lymphoid neoplasms.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
AbstractSince the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
Molecular basis of myelodysplastic/myeloproliferative neoplasms
AbstractThe World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues1 includes within myeloid neoplasms the category "Myelodysplastic/myeloproliferative neoplasms". According to Vardiman et al.,2 these are "clonal myeloid neoplasms that at the time of initial presentation have some clinical, laboratory or morphologic findings that support a diagnosis of myelodysplastic syndrome (MDS), and other findings more consistent with myeloproliferative neoplasm (MPN)". These disorders comprise chronic myelomonocytic leukemia (CMML),3 atypical chronic myeloid leukemia (aCML, BCR-ABL1 negative),4 juvenile myelomonocytic leukemia (JMML),5 and myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U).6 The best characterized of these unclassifiable conditions is the provisional entity defined as refractory anemia with ringed sideroblasts (RARS) associated with marked thrombocytosis (RARS-T).7
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2018 · 0 citations
Faculty Opinions recommendation of The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
AbstractA revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations, and therapeutic strategies for the lymphoid neoplasms. PMID: 26980727 Funding information This work was supported by: NCI NIH HHS, United States Grant ID: P30 CA008748
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
